ChemoCentryx (CCXI) Hits New 52-Week Low at $5.86

Shares of ChemoCentryx Inc (NASDAQ:CCXI) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $5.86 and last traded at $6.29, with a volume of 57400 shares trading hands. The stock had previously closed at $6.47.

A number of equities analysts have recently commented on CCXI shares. BidaskClub lowered shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th. Zacks Investment Research lowered shares of ChemoCentryx from a “buy” rating to a “sell” rating in a research report on Friday, August 11th. Finally, ValuEngine lowered shares of ChemoCentryx from a “hold” rating to a “sell” rating in a research report on Saturday, October 21st. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $8.25.

ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.13. research analysts predict that ChemoCentryx Inc will post -0.67 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. increased its position in ChemoCentryx by 1.7% during the second quarter. American Century Companies Inc. now owns 41,442 shares of the biopharmaceutical company’s stock worth $388,000 after acquiring an additional 698 shares during the period. Wells Fargo & Company MN increased its position in ChemoCentryx by 3.2% during the second quarter. Wells Fargo & Company MN now owns 23,595 shares of the biopharmaceutical company’s stock worth $221,000 after acquiring an additional 729 shares during the period. Teachers Advisors LLC increased its holdings in ChemoCentryx by 3.9% in the 2nd quarter. Teachers Advisors LLC now owns 41,878 shares of the biopharmaceutical company’s stock valued at $392,000 after buying an additional 1,590 shares during the period. The Manufacturers Life Insurance Company increased its holdings in ChemoCentryx by 14.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,514 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 2,852 shares during the period. Finally, Voya Investment Management LLC increased its holdings in ChemoCentryx by 22.8% in the 2nd quarter. Voya Investment Management LLC now owns 15,984 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 2,965 shares during the period. 48.89% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “ChemoCentryx (CCXI) Hits New 52-Week Low at $5.86” was reported by Stock Observer and is the property of of Stock Observer. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.thestockobserver.com/2017/12/08/chemocentryx-ccxi-hits-new-52-week-low-at-5-86.html.

About ChemoCentryx

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Receive News & Ratings for ChemoCentryx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply